UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
40.23
+0.23 (0.57%)
At close: Jul 17, 2026, 4:00 PM EDT
41.03
+0.80 (1.99%)
After-hours: Jul 17, 2026, 4:38 PM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $50.96M in the quarter ending March 31, 2026, with 151.60% growth. This brings the company's revenue in the last twelve months to $140.49M, up 52.92% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth.
Revenue (ttm)
$140.49M
Revenue Growth
+52.92%
P/S Ratio
13.95
Revenue / Employee
$471,453
Employees
298
Market Cap
1.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Harmony Biosciences Holdings | 899.11M |
| Nuvation Bio | 143.05M |
| AbCellera Biologics | 79.21M |
| Viridian Therapeutics | 70.92M |
| Ocular Therapeutix | 52.04M |
| Monte Rosa Therapeutics | 42.95M |
| Taysha Gene Therapies | 7.47M |
URGN News
- 2 days ago - UroGen Pharma price target raised to $50 from $40 at Oppenheimer - TheFly
- 3 days ago - UroGen Pharma price target raised to $44 from $18 at Goldman Sachs - TheFly
- 3 days ago - UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103 - TheFly
- 3 days ago - UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - GlobeNewsWire
- 10 days ago - UroGen Pharma announces FDA clearance for UGN-501 IND application - TheFly
- 10 days ago - UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 26 days ago - UroGen Pharma Transcript: AGM 2026 - Transcripts
- 5 weeks ago - UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts